SciSparc

SciSparc, Deere & Company, Baidu, Marathon Digital, Tesla: Why These 5 Stocks Are On Investors' Radars Today

SciSparc Signs LOI to Sell 50% Interest in Subsidiary

Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

SciSparc Signs LOI to Sell 50% Interest in Subsidiary

Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

SciSparc Nutraceuticals Signs Agreement With Logistics Facilities, Expected To Optimize Handling and Shipment Processes and Reduce Direct Sales Costs

Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration

SciSparc Nutraceuticals Signs Agreement With Logistics Facilities, Expected To Optimize Handling and Shipment Processes and Reduce Direct Sales Costs

Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know

SciSparc Recent News

SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches

More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050.

SciSparc Announces Buyback Equal To 12% Of Float

SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par value (the “Ordinary Shares”).

SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome

SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study for Tourette Syndrome ("TS").

SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome

TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd.

SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray

The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain.

SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment

SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment

SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins

JV Targets Potential Drugs for Cancers and Infectious Diseases

Initial Positive Results For Cocaine Addiction Treatment Announced

Photo by Annie Spratt on

SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.

SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction

No dedicated treatment currently available for cocaine addiction

SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology

SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome

Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial In Tourette Syndrome

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel

Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

SciSparc And Clearmind Medicine Inc. Collaboration Yields Positive Results For Its Psychedelic Combination Treatment

Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption

SciSparc Reports Developing Cannabinoids Based Acute Pain Relief Alternative To Help Counter Opioid Crisis

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested

On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA.

The Hidden Potential Of The Endocannabinoid System? SciSparc Says Its Portfolio Of Cannabinoids-Derived Drug Candidates Tap The Body's Natural System

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Originally motivated by a belief in the dangerous effects of cannabinoids, research into the endocannabinoid system has since reported a central role it plays in many processes that happen inside the human body.

SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application

Image by Thom Masat on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors

Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption

SciSparc Files Annual Report For Year Ended December 31, 2021 And Provides Corporate Update

TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- SciSparc Ltd.